Insider · CIK 0001162533
Gary S Roubin
Files at NSPR (InspireMD, Inc.). First filing Dec 4, 2023, latest May 8, 2026.
In brief
Gary S Roubin files SEC Form 4 as director at NSPR (InspireMD, Inc.). Since Dec 4, 2023, Gary S Roubin has reported 3 open-market buys worth $333k and 0 open-market sells worth $0, the latest filed on May 8, 2026.
A track record needs three past buys with six months of prices behind them; Gary S Roubin has 1, so none is measured yet.
The newest scored trade: bought $106k of NSPR on May 7, 2026, filed May 8, 2026, scored 61 (notable). In the last 12 months: 1 buy worth $106k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NSPR: InspireMD, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 61Notable | InspireMD, Inc. | $106k 90,000 shares | +12% | +5% from low-58% from high | |
| 43Moderate | InspireMD, Inc. | $100k 41,322 shares | +7% | - | |
| 37Weak | NSPRbuy InspireMD, Inc. | $127k 50,000 shares | +13% | +172% from low-39% from high |
Transactions
Every row this insider has filed, 13 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 18, 2026 | NSPR InspireMD, Inc. | JOther Series J Warrant (right to buy)derivative | -15,313 | $0.00 | $0 | 15,312 | 20 d ago |
| Sep 18, 2026 | NSPR InspireMD, Inc. | JOther Series J Warrant (right to buy)derivative | +15,313 | $0.00 | $0 | 15,313 | 20 d ago |
| Sep 18, 2026 | NSPR InspireMD, Inc. | JOther Series K Warrant (right to buy)derivative | -30,624 | $0.00 | $0 | 0 | 20 d ago |
| Sep 18, 2026 | NSPR InspireMD, Inc. | JOther Series K Warrant (right to buy)derivative | +30,624 | $0.00 | $0 | 30,624 | 20 d ago |
| May 7, 2026 | NSPR InspireMD, Inc. | POpen-market purchase Common Stock | +90,000 | $1.18 | $106k | 834,478 | May 8, 2026 |
| Jan 14, 2026 | NSPR InspireMD, Inc. | AGrant or award Common Stock | +88,053 | $0.00 | $0 | 744,478 | Jan 16, 2026 |
| Oct 7, 2025 | NSPR InspireMD, Inc. | AGrant or award Common Stock | +48,000 | $0.00 | $0 | 656,425 | Oct 9, 2025 |
| Jul 30, 2025 | NSPR InspireMD, Inc. | POpen-market purchase Common Stock | +41,322 | $2.42 | $100k | 608,425 | Aug 1, 2025 |
| Jun 25, 2025 | NSPR InspireMD, Inc. | XIn-the-money exercise Common Stock | +30,624 | $1.38 | $42k | 567,103 | Jul 23, 2025 |
| Jun 25, 2025 | NSPR InspireMD, Inc. | XIn-the-money exercise Series I Warrant (right to buy)derivative | -30,624 | $0.00 | $0 | 0 | Jul 23, 2025 |
| Jan 7, 2025 | NSPR InspireMD, Inc. | AGrant or award Common Stock | +32,491 | $0.00 | $0 | 534,279 | Jan 10, 2025 |
| Jan 7, 2025 | NSPR InspireMD, Inc. | AGrant or award Options to purchase common stock (right to buy)derivative | +14,836 | $0.00 | $0 | 91,743 | Jan 10, 2025 |
| Nov 30, 2023 | NSPR InspireMD, Inc. | POpen-market purchase Common Stock | +50,000 | $2.53 | $127k | 438,902 | Dec 4, 2023 |
Questions about Gary S Roubin
Answered from the filings on this page, as of the latest one.
Is Gary S Roubin buying or selling?
In the last 12 months Gary S Roubin reported 1 open-market buy worth $106k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $106k of NSPR on May 7, 2026. Grants, option exercises and tax withholding are not counted.
How did Gary S Roubin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Gary S Roubin has 1.
Where does Gary S Roubin file Form 4?
Gary S Roubin has filed Form 4 at NSPR (InspireMD, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.